Evidence map›Paper›PMID 36558153›Full record

ArticleMolecules (Basel, Switzerland)2022

Real-Time Monitoring of the Atrazine Degradation by Liquid Chromatography and High-Resolution Mass Spectrometry: Effect of Fenton Process and Ultrasound Treatment.

Junting Hong, Nadia Boussetta, Gérald Enderlin, Nabil Grimi, Franck Merlier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Junting HongUniversité de Technologie de Compiègne, UPJV, CNRS, Enzyme and Cell Engineering, Centre de Recherche Royallieu, CEDEX CS 60319, 60203 Compiègne, France.ORCID 0000-0002-4106-1104
Nadia BoussettaUniversité de Technologie de Compiègne, ESCOM, TIMR (Integrated Transformations of Renewable Matter), Centre de Recherche Royallieu, CEDEX CS 60319, 60203 Compiègne, France.
Gérald EnderlinUniversité de Technologie de Compiègne, ESCOM, TIMR (Integrated Transformations of Renewable Matter), Centre de Recherche Royallieu, CEDEX CS 60319, 60203 Compiègne, France.ORCID 0000-0002-3355-9332
Nabil GrimiUniversité de Technologie de Compiègne, ESCOM, TIMR (Integrated Transformations of Renewable Matter), Centre de Recherche Royallieu, CEDEX CS 60319, 60203 Compiègne, France.ORCID 0000-0002-7804-0438
Franck MerlierUniversité de Technologie de Compiègne, UPJV, CNRS, Enzyme and Cell Engineering, Centre de Recherche Royallieu, CEDEX CS 60319, 60203 Compiègne, France.ORCID 0000-0002-8895-8357
Université de Technologie de Compiègne · FR

Funding

Agence Nationale de la Recherche ANR-001 CPER 2007-2020China Scholarship Council 2020
6 · The paper itself

Abstract

High resolution mass spectrometry (HRMS) was coupled with ultra-high-performance liquid chromatography (uHPLC) to monitor atrazine (ATZ) degradation process of Fenton/ultrasound (US) treatment in real time. Samples were automatically taken through a peristaltic pump, and then analysed by HPLC-HRMS. The injection in the mass spectrometer was performed every 4 min for 2 h. ATZ and its degradation metabolites were sampled and identified. Online Fenton experiments in different equivalents of Fenton reagents, online US experiments with/without

Indexed as

AtrazineChromatography, High Pressure LiquidHydrogen PeroxideIronMass SpectrometryAtrazineFenton's reagentHydrogen PeroxideIronatrazine metaboliteFentononline sampling-LC-HRMSultrasound degradation

Identifiers

PMID36558153
PMCPMC9785566
OpenAlexW4312210108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.